Nanologica AB
4YD
Company Profile
Business description
Nanologica AB develops and manufactures nanoporous silica particles for life science applications. It focuses on two areas: Drug Development and Chromatography. The company's drug delivery platforms are NLAB Spiro and NLAB Silica, which focus on producing medicines for the benefit of patients. Its geographical segments are Sweden, China, India, the United States, and the Rest of the world.
Contact
Forskargatan 20G
SodertaljeSE-151 36
SWET: +46 841074949
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
10 of the cheapest global companies with wide moats
These undervalued stocks of high-quality companies could be attractive investments today.
stocks
Bookworm: Buy and hold inspiration from an unlikely source
Ben Graham was the king of flipping deep value stocks. The best investment of his life came from something very different.
stocks
3 ASX shares to avoid
These shares have surged in price in the last year but are significantly overvalued according to our analysts.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,082.10 | 68.80 | 0.86% |
| CAC 40 | 8,062.21 | 33.93 | 0.42% |
| DAX 40 | 23,118.15 | 131.33 | 0.57% |
| Dow JONES (US) | 41,621.36 | 133.17 | 0.32% |
| FTSE 100 | 8,675.95 | 43.62 | 0.51% |
| HKSE | 24,145.57 | 185.59 | 0.77% |
| NASDAQ | 17,777.37 | 23.29 | 0.13% |
| Nikkei 225 | 37,396.52 | 343.42 | 0.93% |
| NZX 50 Index | 12,166.14 | 100.11 | -0.82% |
| S&P 500 | 5,660.34 | 21.40 | 0.38% |
| S&P/ASX 200 | 7,854.10 | 64.40 | 0.83% |
| SSE Composite Index | 3,426.13 | 6.57 | 0.19% |